GuidelineSchmerz (Berlin, Germany)2026
[German guideline on spinal cord stimulation for chronic neuropathic pain].
Guideline in Schmerz (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidural spinal cord stimulation (SCS) is a neuromodulatory, reversible procedure for the treatment of selected chronic pain conditions, primarily neuropathic in nature. The updated German S3 guideline provides evidence-based recommendations for the use of SCS and dorsal root ganglion stimulation (DRG-S). Key innovations include recent technical advances and increased integration into multimodal pain management. The guideline aims to enhance the care of patients with chronic pain by offering rational, scientifically substantiated recommendations. A systematic literature review was conducted, including meta-analyses and randomized controlled trials, with relevant case reports also taken into account. Publications were evaluated by topic, including fundamentals, indications, methods, complications, quality management, and psychosocial aspects. Recommendations are based on established evidence classifications. Major updates include strong evidence in favor of SCS for diabetic polyneuropathy. For other neuropathies, smaller studies indicate positive effects. SCS is considered the most effective therapy for chronic, postoperative back and leg pain. Additionally, SCS receives a strong recommendation for peripheral arterial occlusive disease (Fontaine stages IIb and III). For complex regional pain syndrome (CRPS), DRG‑S demonstrates superiority over SCS and is preferentially recommended. The guideline addresses all professional groups involved in the care of pain patients and offers practical guidance for therapeutic decision-making in the management of chronic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.